Abstract
We report a novel germline 3536delT mutation in BRCA1 gene, detected in a 43-year-old woman with bilateral ovarian adenocarcinoma. The mutation originates a premature stop codon at position 1154 and has not been documented in any published report to the best of our knowledge.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Venkitaraman AR (2002) Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108:171–182
Narod SA, Foulkes WD (2004) BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 4:665–676
Oldenburg RA, Meijers-Heijboer H, Cornelisse CJ, Devilee P (2007) Genetic susceptibility for breast cancer: how many more genes to be found? Crit Rev Oncol Hematol 63:125–149
Koonin EV, Altschul SF, Bork P (1996) BRCA1 protein products ... Functional motifs. Nat Genet 13:266–268
Salgado J, Zabalegui N, Garcia-Amigot F, Gil MC, Gonzalez MS, Garcia-Foncillas J (2005) Structure-based assessment of BRCA1 and BRCA2 mutations in a small Spanish population. Oncol Rep 14:85–88
Brzovic PS, Keeffe JR, Nishikawa H, Miyamoto K, Fox D 3rd, Fukuda M, Ohta T, Klevit R (2003) Binding and recognition in the assembly of an active BRCA1/BARD1 ubiquitin-ligase complex. Proc Natl Acad Sci USA 100:5646–5651
Baer R, Ludwig T (2002) The BRCA1/BARD1 heterodimer, a tumor suppressor complex with ubiquitin E3 ligase activity. Curr Opin Genet Dev 12:86–91
Manke IA, Lowery DM, Nguyen A, Yaffe MB (2003) BRCT repeats as phosphopeptide-binding modules involved in protein targeting. Science 302:636–639
Yu X, Chini CC, He M, Mer G, Chen J (2003) The BRCT domain is a phospho-protein binding domain. Science 302:639–642
Yu X, Chen J (2004) DNA damage-induced cell cycle checkpoint control requires CtIP, a phosphorylation-dependent binding partner of BRCA1 C-terminal domains. Mol Cell Biol 24:9478–9486
Saal LH, Gruvberger-Saal SK, Persson C et al (2007) Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet. doi: 101038/ng.2007.39
Hodgson SV, Haites NE, Caligo M, Chang-Claude J, Eccles D, Evans G, Moller P, Morrison P, Steel CM, Stoppa-Lyonnet D, Vasen H (2000) A survey of the current clinical facilities for the management of familial cancer in Europe. European Union BIOMED II demonstration project: familial breast cancer: audit of a new development in medical practice in European centres. J Med Genet 37:605–607
Acknowledgments
We are grateful to the patients, and their families, for their participation in our research project. We thank other members of our Clinical Genetics Unit at the University Clinic of Navarra for their support and encouragement.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Salgado, J., Gil, C., Robles, M. et al. A novel BRCA1 mutation in a Spanish patient with ovarian cancer. Breast Cancer Res Treat 113, 71–73 (2009). https://doi.org/10.1007/s10549-008-9907-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-008-9907-6